Glucagon-like peptide-1 receptor agonists (GLP-1 RAs)—along with emerging dual and triple incretin co-agonists—have transformed the therapeutic landscape of type 2 diabetes mellitus (T2DM) and obesity, achieving sustained weight loss of 15–20%, enhanced glycemic control, and cardiovascular protection, as demonstrated in pivotal trials of once-weekly semaglutide and tirzepatide [1,2]. The gene discussed is GLP1R; the disease is diabetes mellitus.